SEC Form S-1 filed by Lakewood-Amedex Biotherapeutics Inc.

Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU programSARASOTA, Fla., June 25, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that David G. Armstrong, DPM, M.D., Ph.D., Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, has accepted the position of Study Chair for the Company's Phase 2a clinical trial evaluating Nu-3 for the treatment of infected diabe

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

New patent enhances global IP footprint and pipeline expansion opportunitiesSARASOTA, Fla., June 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the expansion of the Company's patent portfolio with the issuance of a new patent in Australia protecting Bisphosphocin® compounds that are being explored in a range of antimicrobial infections including complicated urinary tract infections and pulmonary infections.

424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

8-K - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

4 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listingSARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (NASDAQ:ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step in strengthening the Company's governance